Literature DB >> 15161652

Kinetics of gene expression in murine cutaneous graft-versus-host disease.

Philip B Sugerman1, Sara B Faber, Lucy M Willis, Aleksandra Petrovic, George F Murphy, Jacques Pappo, David Silberstein, Marcel R M van den Brink.   

Abstract

The kinetics of gene expression associated with the development of cutaneous graft-versus-host disease (GVHD) were examined in a mouse model of MHC-matched allogeneic hematopoietic stem cell transplantation. Ear skin was obtained from recipient mice with or without GVHD between 7 and 40 days after transplantation for histopathological analysis and gene expression profiling. Gene expression patterns were consistent with early infiltration and activation of CD8(+) T and mast cells, followed by CD4(+) T, natural killer, and myeloid cells. The sequential infiltration and activation of effector cells correlated with the histopathological development of cutaneous GVHD and was accompanied by up-regulated expression of many chemokines and their receptors (CXCL-1, -2, -9, and -10; CCL-2, -5, -6, -7, -8, -9, -11, and -19; CCR-1 and CCR-5), adhesion molecules (ICAM-1, CD18, Ly69, PSGL-1, VCAM-1), molecules involved in antigen processing and presentation (TAP1 and TAP2, MHC class I and II, CD80), regulators of apoptosis (granzyme B, caspase 7, Bak1, Bax, and BclII), interferon-inducible genes (STAT1, IRF-1, IIGP, GTPI, IGTP, Ifi202A), stimulators of fibroblast proliferation and matrix synthesis (interleukin-1beta, transforming growth factor-beta1), and markers of keratinocyte proliferation (keratins 5 and 6), and differentiation (small proline-rich proteins 2E and 1B). Many acute-phase proteins were up-regulated early in murine cutaneous GVHD including serum amyloid A2 (SAA2), SAA3, serpins a3g and a3n, secretory leukocyte protease inhibitor, and metallothioneins 1 and 2. The kinetics of gene expression were consistent with the evolution of cutaneous pathology as well as with current models of disease progression during cutaneous GVHD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161652      PMCID: PMC1615752          DOI: 10.1016/S0002-9440(10)63776-5

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  91 in total

Review 1.  Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm.

Authors:  T A Springer
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

Review 2.  The Ly-49 and NKR-P1 gene families encoding lectin-like receptors on natural killer cells: the NK gene complex.

Authors:  W M Yokoyama; W E Seaman
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

3.  Macrosialin, a mouse macrophage-restricted glycoprotein, is a member of the lamp/lgp family.

Authors:  C L Holness; R P da Silva; J Fawcett; S Gordon; D L Simmons
Journal:  J Biol Chem       Date:  1993-05-05       Impact factor: 5.157

4.  Antigen-driven induction of CD11c on intestinal intraepithelial lymphocytes and CD8+ T cells in vivo.

Authors:  J W Huleatt; L Lefrançois
Journal:  J Immunol       Date:  1995-06-01       Impact factor: 5.422

5.  Serine proteinases are regionally segregated within mast cell granules.

Authors:  D Whitaker-Menezes; N M Schechter; G F Murphy
Journal:  Lab Invest       Date:  1995-01       Impact factor: 5.662

6.  Interleukin-12 inhibits murine graft-versus-host disease.

Authors:  M Sykes; G L Szot; P L Nguyen; D A Pearson
Journal:  Blood       Date:  1995-09-15       Impact factor: 22.113

7.  Kinetic and organ-specific patterns of cytokine expression in acute graft-versus-host disease.

Authors:  K S Baker; R D Allen; J B Roths; C L Sidman
Journal:  Bone Marrow Transplant       Date:  1995-04       Impact factor: 5.483

8.  Role of mast cells in early epithelial target cell injury in experimental acute graft-versus-host disease.

Authors:  G F Murphy; H Sueki; C Teuscher; D Whitaker; R Korngold
Journal:  J Invest Dermatol       Date:  1994-04       Impact factor: 8.551

9.  Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers.

Authors:  P G Schlegel; M Vaysburd; Y Chen; E C Butcher; N J Chao
Journal:  J Immunol       Date:  1995-10-15       Impact factor: 5.422

10.  Promotion of mouse fibroblast collagen gene expression by mast cells stimulated via the Fc epsilon RI. Role for mast cell-derived transforming growth factor beta and tumor necrosis factor alpha.

Authors:  J R Gordon; S J Galli
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

View more
  26 in total

1.  Villitis of unknown etiology is associated with a distinct pattern of chemokine up-regulation in the feto-maternal and placental compartments: implications for conjoint maternal allograft rejection and maternal anti-fetal graft-versus-host disease.

Authors:  Mi Jeong Kim; Roberto Romero; Chong Jai Kim; Adi L Tarca; Sovantha Chhauy; Christopher LaJeunesse; Deug-Chan Lee; Sorin Draghici; Francesca Gotsch; Juan Pedro Kusanovic; Sonia S Hassan; Jung-Sun Kim
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

2.  Absence of P-selectin in recipients of allogeneic bone marrow transplantation ameliorates experimental graft-versus-host disease.

Authors:  Sydney X Lu; Amanda M Holland; Il-Kang Na; Theis H Terwey; Onder Alpdogan; Jhoanne L Bautista; Odette M Smith; David Suh; Christopher King; Adam Kochman; Vanessa M Hubbard; Uttam K Rao; Nury Yim; Chen Liu; Alvaro C Laga; George Murphy; Robert R Jenq; Johannes L Zakrzewski; Olaf Penack; Lindsay Dykstra; Kevin Bampoe; Lia Perez; Bruce Furie; Barbara Furie; Marcel R M van den Brink
Journal:  J Immunol       Date:  2010-07-09       Impact factor: 5.422

3.  Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease.

Authors:  Christian A Wysocki; Qi Jiang; Angela Panoskaltsis-Mortari; Patricia A Taylor; Karen P McKinnon; Lishan Su; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2005-07-07       Impact factor: 22.113

4.  CXCR3-mediated skin homing of autoreactive CD8 T cells is a key determinant in murine graft-versus-host disease.

Authors:  Vadim A Villarroel; Naoko Okiyama; Gaku Tsuji; Jay T Linton; Stephen I Katz
Journal:  J Invest Dermatol       Date:  2014-01-03       Impact factor: 8.551

Review 5.  Chronic inflammation of the placenta: definition, classification, pathogenesis, and clinical significance.

Authors:  Chong Jai Kim; Roberto Romero; Piya Chaemsaithong; Jung-Sun Kim
Journal:  Am J Obstet Gynecol       Date:  2015-10       Impact factor: 8.661

6.  Sequential activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3.

Authors:  Hui-Hui Ma; Judy Ziegler; Cuiling Li; Antonia Sepulveda; Ahmed Bedeir; Jennifer Grandis; Suzanne Lentzsch; Markus Y Mapara
Journal:  Cell Immunol       Date:  2011-02-04       Impact factor: 4.868

Review 7.  Leukocyte migration and graft-versus-host disease.

Authors:  Christian A Wysocki; Angela Panoskaltsis-Mortari; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2005-02-08       Impact factor: 22.113

8.  Efficacy of azithromycin in preventing lethal graft-versus-host disease.

Authors:  S Iwamoto; E Azuma; T Kumamoto; M Hirayama; T Yoshida; M Ito; K Amano; M Ido; Y Komada
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

9.  Organ-derived dendritic cells have differential effects on alloreactive T cells.

Authors:  Theo D Kim; Theis H Terwey; Johannes L Zakrzewski; David Suh; Adam A Kochman; Megan E Chen; Chris G King; Chiara Borsotti; Jeremy Grubin; Odette M Smith; Glenn Heller; Chen Liu; George F Murphy; Onder Alpdogan; Marcel R M van den Brink
Journal:  Blood       Date:  2008-01-04       Impact factor: 22.113

10.  Characterization of the acute temporal changes in excisional murine cutaneous wound inflammation by screening of the wound-edge transcriptome.

Authors:  Sashwati Roy; Savita Khanna; Cameron Rink; Sabyasachi Biswas; Chandan K Sen
Journal:  Physiol Genomics       Date:  2008-05-06       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.